Apr 26, 2022 5:18pm EDT SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Apr 22, 2022 8:15am EDT SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Apr 22, 2022 8:00am EDT SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections
Apr 20, 2022 8:30am EDT SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal
Apr 19, 2022 8:30am EDT SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives
Mar 29, 2022 7:00am EDT SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 24, 2022 8:30am EDT SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update
Mar 08, 2022 8:30am EST SCYNEXIS Named to Fast Company’s 2022 List of the World’s Most Innovative Companies
